SCHEMBL29506574

SCHEMBL29506574

CN1CCN(c2ccc(Nc3ncc4c(n3)N3CCN=C3N(c3cccnc3)C4=O)cc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CDK4 P11802 4/20 0.54
▸ AURKA O14965 1/20 0.54
▸ WEE1 P30291 6/20 0.50
▸ TNK2 Q07912 1/20 0.48
▸ FGFR4 P22455 1/20 0.47
▸ CCND1 P24385 2/20 0.47
▸ CCND2 P30279 1/20 0.47
▸ CCND3 P30281 1/20 0.47
▸ EGFR P00533 3/20 0.47
▸ CDK2 P24941 1/20 0.46
▸ KDR P35968 1/20 0.46
▸ GSK3B P49841 1/20 0.46
▸ JAK2 O60674 2/20 0.46
▸ BRD4 O60885 1/20 0.46
▸ FLT3 P36888 2/20 0.45
▸ ALK Q9UM73 1/20 0.45
▸ SRC P12931 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21373388 1.00 CDK4 (0.54) CDK4AURKAWEE1TNK2FGFR4
SCHEMBL21373412 0.92 CDK4 (0.54) CDK4WEE1TNK2FGFR4CCND1
SCHEMBL21373409 0.91 WEE1 (0.49) CDK4AURKAWEE1TNK2FGFR4
SCHEMBL21373334 0.90 WEE1 (0.49) CDK4AURKAWEE1TNK2FGFR4
SCHEMBL21373308 0.88 WEE1 (0.53) WEE1FGFR4EGFRJAK2BRD4
SCHEMBL29506568 0.88 FLT3 (0.53) CDK4WEE1TNK2CCND1CCND2
SCHEMBL21373472 0.88 FLT3 (0.53) CDK4WEE1TNK2CCND1CCND2
SCHEMBL21373461 0.88 WEE1 (0.53) CDK4WEE1TNK2FGFR4CCND1
SCHEMBL5235004 0.86 WEE1 (0.54) CDK4WEE1TNK2CCND1CCND2
SCHEMBL29506599 0.86 WEE1 (0.54) CDK4WEE1TNK2CCND1CCND2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118338905-A Use of Wee1 kinase inhibitors in the treatment of cancer 上海瑛派药业有限公司 2024-07-12 — — CN claimed
CN-117202908-A Use of Wee1 kinase inhibitors in the treatment of cancer diseases 上海瑛派药业有限公司 2023-12-08 — — CN claimed
WO-2023093840-A1 USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) 2023-06-01 — — WO claimed
WO-2022188802-A1 USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) 2022-09-15 — — WO claimed
CN-109906227-B 8, 9-dihydroimidazo [1,2-a ] pyrimido [5,4-e ] pyrimidin-5 (6H) -ones 上海瑛派药业有限公司 2022-03-11 — — CN claimed
WO-2025074275-A1 COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS AND WEE1 INHIBITORS REPARE THERAPEUTICS, INC. (CA) 2025-04-10 — — WO disclosed
CN-118338905-A Use of Wee1 kinase inhibitors in the treatment of cancer 上海瑛派药业有限公司 2024-07-12 — — CN disclosed
CN-117202908-A Use of Wee1 kinase inhibitors in the treatment of cancer diseases 上海瑛派药业有限公司 2023-12-08 — — CN disclosed
WO-2023093840-A1 USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) 2023-06-01 — — WO disclosed
WO-2022188802-A1 USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) 2022-09-15 — — WO disclosed
CN-109906227-B 8, 9-dihydroimidazo [1,2-a ] pyrimido [5,4-e ] pyrimidin-5 (6H) -ones 上海瑛派药业有限公司 2022-03-11 — — CN disclosed
Send feedback